News in Brief: DMTs reduce disability by 50-70% in paediatric onset MS; Stroke location and cognitive impairment; Warning letters curb opioid prescribing

Risk of persistent disability falls by 50-70% in paediatric onset MS  The risk of developing persistent disability following a multiple sclerosis diagnosis in childhood  has more than halved with greater availability and earlier use of the newer disease-modifying therapies (DMTs), suggests new international research. In the largest paediatric onset Multiple Sclerosis (POMS) cohort analysis, including ...

Already a member?

Login to keep reading.

© 2021 the limbic